The APIS team will be exhibiting and presenting at the 13th World Clinical Biomarker & CDx 2023 in Boston.

Be sure not to miss Program Lead, Joanna Gorniak, PhD, presenting on Day 2, Friday 8th September at 4 PM with her talk titled ‘HER2 Stratification with a Novel Diagnostic Test’.

APIS is leveraging the transformational power of systems biology, innovative synthetic antibody technologies, and genomic big data to directly address the historical failures of translating biomarkers into clinical utility.

Operating under an ISO 13485 QMS, APIS seeks to develop and manufacture proprietary and client derived disease- and tissue-agnostic biomarkers as IVD tests (MDx, CDx and CoDx), maximising the benefit to both patients and stakeholders in either a centralised or de-centralised laboratory setting.

Use this link to contact us and schedule a meeting.